Randomized trial · people
SS-31 did not significantly cut infarct size in EMBRACE STEMI
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a randomized human trial in heart attack patients having PCI, SS-31 was well tolerated but did not significantly reduce heart muscle damage compared with placebo.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2016
- Journal
- Eur Heart J
What they tested
The team tested whether a 1-hour infusion of SS-31 (MTP-131) would reduce the extra heart damage that can follow the return of blood flow in people having primary PCI for a first major heart attack.
How the study was done
A multicenter, randomized, double-blind, placebo-controlled Phase 2a trial in people having their first anterior STEMI (a major heart attack shown by a specific ECG pattern) caused by a blockage in the proximal or mid left anterior descending (LAD) artery, all undergoing primary PCI (a catheter procedure to reopen the artery). The SS-31 arm received an infusion of 0.05 mg/kg/h for 1 h, compared with placebo.

What they found
SS-31 did not significantly reduce the main measure, infarct size (how much heart muscle died) judged by the total CK-MB released over 72 h. CK-MB is a heart-damage marker in the blood. The total was 5570 ± 486 ng h/mL in the SS-31 arm and 5785 ± 426 ng h/mL in the placebo arm. SS-31 also did not improve the pre-planned MRI, angiography, ECG or clinical outcomes, and it was safe and well tolerated.
What it doesn’t show
This was a mid-stage Phase 2a trial limited to first-time anterior heart attacks from an LAD blockage, so it does not show how other heart attack patients would respond. It tested a single 1-hour infusion at one dose rate and does not show what longer or different dosing would do.
The paper
Gibson et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.